Increases in nuclear STAT5 have been linked to early recurrence and poor survival outcomes in prostate cancer, and overactivation of STAT3 that is associated with decreased survival and high risk of recurrence in renal cell carcinoma, glioblastoma, cervical cancer, colorectal cancer, and melanoma [1]. Here, STAT5A is linked to prostate cancer.